View Item 

Show simple item record

Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction
dc.contributor.authorDocherty, Kieran F.
dc.contributor.authorFerreira, Jo�o Pedro
dc.contributor.authorSharma, Abhinav
dc.contributor.authorGirerd, Nicolas
dc.contributor.authorGregson, John
dc.contributor.authorDuarte, Kevin
dc.contributor.authorPetrie, Mark C.
dc.contributor.authorJhund, Pardeep S.
dc.contributor.authorDickstein, Kenneth
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorPitt, Bertram
dc.contributor.authorRossignol, Patrick
dc.contributor.authorZannad, Faiez
dc.contributor.authorMcMurray, John J.V.
dc.date.accessioned2020-06-03T15:24:28Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-06-03T15:24:28Z
dc.date.issued2020-05
dc.identifier.citationDocherty, Kieran F.; Ferreira, Jo�o Pedro ; Sharma, Abhinav; Girerd, Nicolas; Gregson, John; Duarte, Kevin; Petrie, Mark C.; Jhund, Pardeep S.; Dickstein, Kenneth; Pfeffer, Marc A.; Pitt, Bertram; Rossignol, Patrick; Zannad, Faiez; McMurray, John J.V. (2020). "Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction." European Journal of Heart Failure 22(5): 848-855.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/155549
dc.description.abstractAimsTo develop a risk model for sudden cardiac death (SCD) in high‐risk acute myocardial infarction (AMI) survivors.Methods and resultsData from the Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction trial (CAPRICORN) and the Valsartan in Acute Myocardial Infarction Trial (VALIANT) were used to create a SCD risk model (with non‐SCD as a competing risk) in 13 202 patients. The risk model was validated in the Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study (EPHESUS). The rate of SCD was 3.3 (95% confidence interval 3.0–3.5) per 100 person‐years over a median follow‐up of 2.0 years. Independent predictors of SCD included age > 70 years; heart rate ≥ 70 bpm; smoking; Killip class III/IV; left ventricular ejection fraction ≤30%; atrial fibrillation; history of prior myocardial infarction, heart failure or diabetes; estimated glomerular filtration rate < 60 mL/min/1.73 m2; and no coronary reperfusion or revascularisation therapy for index AMI. The model was well calibrated and showed good discrimination (C‐statistic = 0.72), including in the early period after AMI. The observed 2‐year event rates increased steeply with each quintile of risk score (1.9%, 3.6%, 6.2%, 9.0%, 13.4%, respectively).ConclusionAn easy to use SCD risk score developed from routinely collected clinical variables in patients with heart failure, left ventricular systolic dysfunction or both, early after AMI was superior to left ventricular ejection fraction. This score might be useful in identifying patients for future trials testing treatments to prevent SCD early after AMI.
dc.publisherJohn Wiley & Sons, Ltd.
dc.subject.otherHeart failure
dc.subject.otherAcute myocardial infarction
dc.subject.otherSudden cardiac death
dc.subject.otherRisk model
dc.subject.otherLeft ventricular systolic dysfunction
dc.titlePredictors of sudden cardiac death in high‐risk patients following a myocardial infarction
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155549/1/ejhf1694.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155549/2/ejhf1694_am.pdf
dc.identifier.doi10.1002/ejhf.1694
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceFine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496 – 509.
dc.identifier.citedreferenceOlgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, Zweibel S, Buxton AE, Elayi CS, Chung EH, Rashba E, Borggrefe M, Hue TF, Maguire C, Lin F, Simon JA, Hulley S, Lee BK; VEST Investigators. Wearable cardioverter–defibrillator after myocardial infarction. N Engl J Med 2018; 379: 1205 – 1215.
dc.identifier.citedreferenceDickstein K, Bebchuk J, Wittes J. The high‐risk myocardial infarction database initiative. Prog Cardiovasc Dis 2012; 54: 362 – 366.
dc.identifier.citedreferenceDargie HJ. Design and methodology of the CAPRICORN trial – a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2000; 2: 325 – 332.
dc.identifier.citedreferenceBenjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, De FSD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jim’nez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, RH MK, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfghi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation 2017; 135: e146 – e603.
dc.identifier.citedreferenceOttervanger JP, Ramdat Misier AR, Dambrink JH, de Boer MJ, Hoorntje JCA, Gosselink ATM, Suryapranata H, Reiffers S, van ’t Hof AW; Zwolle Myocardial Infarction Study Group. Mortality in patients with left ventricular ejection fraction ≤30% after primary percutaneous coronary intervention for ST‐elevation myocardial infarction. Am J Cardiol 2007; 100: 793 – 797.
dc.identifier.citedreferenceAdabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL. Sudden death after myocardial infarction. JAMA 2008; 300: 2022 – 2029.
dc.identifier.citedreferenceSolomon SD, Zelenkofske S, McMurray JJ, Finn P V, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA; Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581 – 2588.
dc.identifier.citedreferencePriori SG, Blomstrom‐Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez‐Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793 – 2867.
dc.identifier.citedreferenceAl‐Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death; a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72: e91 – e220.
dc.identifier.citedreferenceHohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter‐defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481 – 2488.
dc.identifier.citedreferenceSteinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz‐Jach Z, Sredniawa B, Lupkovics G, Hofgärtner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J; IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361: 1427 – 1436.
dc.identifier.citedreferenceDargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385 – 1390.
dc.identifier.citedreferencePitt B, Williams G, Remme W, Martinez F, Lopez‐Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79 – 87.
dc.identifier.citedreferencePitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309 – 1321.
dc.identifier.citedreferenceDickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999; 83: 477 – 481.
dc.identifier.citedreferenceDickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752 – 760.
dc.identifier.citedreferencePfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J 2000; 140: 727 – 750.
dc.identifier.citedreferencePfeffer MA, McMurray JJ, Velazquez EJ, Rouleau J‐L, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893 – 1906.
dc.identifier.citedreferencePiccini JP, Zhang M, Pieper K, Solomon SD, Al‐Khatib SM, Van de Werf F, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. Eur Heart J 2010; 31: 211 – 221.
dc.identifier.citedreferenceWittenberg SM, Cook JR, Hall WJ, McNitt S, Zareba W, Moss AJ; Multicenter Automatic Defibrillator Implantation Trial. Comparison of efficacy of implanted cardioverter‐defibrillator in patients with versus without diabetes mellitus. Am J Cardiol 2005; 96: 417 – 419.
dc.identifier.citedreferenceGoldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, Greenberg H, Case RB; Multicenter Automatic Defibrillator Implantation Trial‐II Investigators. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006; 98: 485 – 490.
dc.identifier.citedreferenceIakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug‐eluting stents. JAMA 2005; 293: 2126 – 2130.
dc.identifier.citedreferenceLewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003; 42: 1446 – 1453.
dc.identifier.citedreferenceLewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 2008; 29: 748 – 756.
dc.identifier.citedreferenceHjalmarson Å, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547 – 553.
dc.identifier.citedreferenceRea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137: 494 – 500.
dc.identifier.citedreferenceWeir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 2006; 97: 13F – 25F.
dc.identifier.citedreferenceDesai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD. Effect of the angiotensin‐receptor‐neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990 – 1997.
dc.identifier.citedreferenceAl’Aref SJ, Anchouche K, Singh G, Slomka PJ, Kolli KK, Kumar A, Pandey M, Maliakal G, van Rosendael AR, Beecy AN, Berman DS, Leipsic J, Nieman K, Andreini D, Pontone G, Schoepf UJ, Shaw LJ, Chang HJ, Narula J, Bax JJ, Guan Y, Min JK. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. Eur Heart J 2019; 40: 1975 – 1986.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1694.pdf
Size:
848.3KB
Format:
PDF
View/Open
Name:
ejhf1694_am.pdf
Size:
1.072MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.